7 Dec 2015 15:57
For immediate release | 07 December 2015 |
ABCAM PLC
("Abcam" or "the Company")
Director / PDMR Shareholding - Replacement
The following replaces the 'Director / PDMR Shareholding' announcement released on 7 December 2015 at 13:59 under RNS No. 2336I.
The change is identified with an asterisk (*)
The full amended text is shown below:
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, has been notified that on Friday 4 December 2015, the Trustees of the Abcam plc Share Incentive Plan ("Plan") purchased Ordinary Shares of 0.2* pence each in the Company at a price of £5.957* per share under the Plan's Dividend Re-Investment on behalf of the persons listed below:
Director | Number of Shares |
Alan Hirzel, Chief Executive Officer | 43 |
Jim Warwick, Chief Operating Officer | 199 |
Jeff Iliffe, Chief Financial Officer | 199 |
PDMR | Number of Shares |
Suzanne Smith, Chief Legal Officer & Company Secretary | 11 |
No consideration was paid by the above grantees in respect of the Dividend Re-Investment. The shares purchased will be subject to a three year holding period.
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Suzanne Smith, Company Secretary
| |
J.P.Morgan Cazenove - Nominated Adviser & Corporate Broker | + 44 (0) 20 7742 4000 |
James Mitford / Alex Bruce - Nominated Adviser | |
Notes to Editors
About Abcam
Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com